• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

39.84 +1.96 (+5.17%)
Delayed Quote Updated: 4:00 PM EDT, Oct 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,509,141
Open 37.77
Bid (Size) 35.00 (100)
Ask (Size) 46.88 (100)
Prev. Close 37.88
Today's Range 37.77 - 40.52
52wk Range 37.54 - 59.68
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
October 19, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Russell 2000 Stock with Exciting Potential and 2 We Ignore
October 14, 2026
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou... 
Via StockStory
Topics Supply Chain

Performance

52-Week Range 33.2% below 52-week high
39.84
37.5452W Low 59.6852W High
1 Week 8.0% below 1-week high
37.541W Low 43.291W High

Supernus Pharmaceuticals, Inc. - Common Stock (SUPN) traded between $37.54 and $59.68 over the past 52 weeks and last traded at $39.84, 33.2% below its 52-week high. Over the past week it ranged between $37.54 and $43.29.

Past 12 Months
-5.2%
-6.9%
-16.0%
-22.3%
-19.5%
-22.8%
1W -$2.17
1M -$2.94
3M -$7.58
6M -$11.41
YTD -$9.63
1Y -$11.75

SUPN was -22.8% over the past year, -22.3% over six months, -19.5% year to date, -5.2% in the last week.

12 Months vs Market
SUPN
-22.8%
DIA
+11.1%
SPY
+14.2%
QQQ
+17.5%
IWM
+9.3%

Over the past 12 months SUPN returned -22.8% versus DIA (Dow) +11.1%, SPY (S&P 500) +14.2%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +9.3%.

Volume & Liquidity 1.89× 3-mo avg
Today 1,509,141 3-mo avg 799.1K
1W
1.2M
1M
814.0K
3M
799.1K
6M
785.6K
YTD
756.0K
1Y
773.6K

SUPN most recently traded 1,509,141 shares against a 3-month average daily volume of 799.1K.

More News

Read More
News headline image
1 Healthcare Stock Worth Your Attention and 2 We Turn Down
October 09, 2026
Via StockStory
News headline image
1 Unprofitable Stock with Impressive Fundamentals and 2 We Avoid
September 30, 2026
Via StockStory
News headline image
2 Growth Stocks to Add to Your Roster and 1 We Question
September 28, 2026
Via StockStory
Topics Credit Cards
News headline image
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
September 24, 2026
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
September 21, 2026
Via StockStory
Topics Stocks Supply Chain
News headline image
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
September 17, 2026
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Cash-Heavy Stocks Walking a Fine Line
September 16, 2026
Via StockStory
News headline image
1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 Facing Headwinds
September 08, 2026
Via StockStory
News headline image
Supernus Pharmaceuticals to Participate in September Investor Conferences
September 02, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Out-of-Favor Stocks We’re Skeptical Of
September 02, 2026
Via StockStory
News headline image
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
August 31, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
August 29, 2026
From Halper Sadeh LLC
Via Business Wire
News headline image
3 Small-Cap Stocks with Open Questions
August 25, 2026
Via StockStory
News headline image
1 Healthcare Stock with Exciting Potential and 2 We Ignore
August 18, 2026
Via StockStory
Topics Retirement
News headline image
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
August 17, 2026
Via Benzinga
Topics Earnings
News headline image
3 Russell 2000 Stocks We Approach with Caution
August 14, 2026
Via StockStory
News headline image
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
August 07, 2026
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Why Supernus Pharmaceuticals Stock Topped the Market Today ↗
August 03, 2026
Via The Motley Fool
News headline image
Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders
August 03, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
August 03, 2026
From Halper Sadeh LLC
Via Business Wire
News headline image
Supernus Pharmaceuticals Q2 Earnings Call Highlights ↗
August 03, 2026
Via MarketBeat
Topics Earnings
What's going on in today's pre-market session ↗
August 03, 2026
Via Chartmill
News headline image
Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%
August 03, 2026
Via StockStory

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 39.84
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 10/19/26 04:00 PM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.12B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap